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7Foreword
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)  
is the central source of comprehensive information on drugs in the European  
Union. Its main task is to collect and disseminate data on the use of substances  
controlled by the United Nations drug conventions. However, in recent years,  
the Centre has become increasingly active in monitoring new substances not listed  
in these conventions, but which may pose health and social risks to our societies. 
Today, this activity is carried out under the terms of a specific legal instrument 
adopted by the Council of the European Union in 2005 — Council Decision 
2005/387/JHA on the information exchange, risk-assessment and control of  
new psychoactive substances.
This Decision allows the EU institutions and Member States to act on all new and 
potentially threatening narcotic and psychotropic drugs (natural and synthetic 
alike) that appear on the European drug scene. Under the terms of the Decision, 
the EMCDDA and Europol, in collaboration with their respective networks, the 
European Medicines Agency (EMEA) and the European Commission, play a 
central role in detecting new psychoactive drugs, assessing their risks and paving 
the way for eventual control measures.
In this process, the EMCDDA’s Scientific Committee — extended by additional 
experts from the Member States, the European Commission, Europol and the 
EMEA — assesses the possible health and social risks of the newly identified drug 
and the implications of placing it under control. A Risk Assessment Report is then 
presented to the Commission and the Council for consideration.
It is with great pleasure that I present the guidelines for the risk assessment of new 
psychoactive substances. In order to support the implementation of the Council 
Decision, this innovative work compiled in a systematic manner by professionals 
from a range of scientific disciplines ensures that new substances are subjected to 
as rigorous scientific assessment as is possible. 
The considerable work required to prepare the guidelines is the result of a broad 
collaboration of experts from both within and outside the EMCDDA, namely the 
EMCDDA’s Scientific Committee, the Commission, Europol, the EMEA and the 
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Member States. It is an illustration of the cooperation that is needed when trying 
to respond effectively to the ever-evolving new drugs phenomenon. 
I am confident that these concise guidelines clearly present the steps, procedures, 
roles and responsibilities of all partners involved in this process and will therefore 
be a vital tool in the risk assessment of new psychoactive substances. 
Wolfgang Götz
Director, EMCDDA
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Introduction
These guidelines are a revision of the Guidelines for the risk assessment of new 
synthetic drugs (1). A revision was deemed necessary as a result of the 
replacement of the Joint Action of 16 June 1997 concerning the information 
exchange, risk-assessment and control of new synthetic drugs (2) (hereafter the 
‘Joint Action’) by Council Decision 2005/387/JHA of 10 May 2005 on the 
information exchange, risk-assessment and control of new psychoactive 
substances (3) (hereafter the ‘Council Decision’). An evaluation of the Joint Action 
concluded that it needed a re-orientation with respect to its objective and scope. 
Furthermore, the evaluation made clear that clarification of the applicable 
procedures and enhancement of the transparency of its operations were 
necessary (4). 
The principal aim of these guidelines is to put in place a sound methodological 
and procedural basis for carrying out each risk assessment. The risk assessment 
has regard to the health and social risks of the use of, manufacture of, and traffic 
in the new psychoactive substance, the involvement of organised crime and the 
possible consequences of control measures.
The guidelines fully reflect the scope and requirements of Council Decision 
2005/387/JHA as well as the knowledge accumulated in the Member States and 
by the EMCDDA over the years. The text includes appropriate references to the 
legal framework and the full text of the Decision is provided in the Appendix for 
added clarity.
The guidelines were finalised and adopted by the EMCDDA’s Scientific Committee 
during its 29th meeting on 17–18 November 2008. However, they are the result of 
extensive developmental work undertaken by the EMCDDA through a complex 
and laborious process. In this respect, I would like to acknowledge the 
(1) EMCDDA (1999), Guidelines for the risk assessment of new synthetic drugs, 
European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
(2) OJ L 167, 25.6.1997.
(3) OJ L 127, 20.5.2005.
(4) Proposal for a Council decision on the information exchange, risk-assessment and  
the control of new narcotic drugs and new synthetic drugs (Brussels, 3.10.2003; 
COM (2003) 560 final 2003/0215 (CNS)).
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considerable commitment of my colleagues from the Scientific Committee who 
enjoyed a fruitful collaboration with EMCDDA staff and experts from the Dutch 
National Institute for Public Health and the Environment (RIVM) and the Dutch 
National Institute of Mental Health and Addiction (Trimbos Institute). Furthermore, 
the contributions made by the European Commission, Europol and the European 
Medicines Agency (EMEA) were crucial for ensuring the truly multidisciplinary 
approach of the guidelines.
Finally, any risk assessment at an early stage of knowledge and scientific evidence 
will inevitably contain some degree of inconclusiveness. However, I am optimistic 
that through their implementation, the risk assessment guidelines will be further 
operationalised so as to allow the EMCDDA’s Scientific Committee to present to the 
Commission and the Council analytical and sound evidence-based risk assessment 
reports.
Dr Michael Farrell
Chair of the EMCDDA’s Scientific Committee


15
Chapter 1
Legal basis and scope
1.1 Legal basis
The legal basis for the risk assessment is given in the Council Decision, particularly 
Article 6. The Council Decision in its turn has regard to the Treaty of the European 
Union (5), in particular Articles 29, 31(1)(e) and 34 therein. These articles are 
provisions on police and judicial cooperation in criminal matters (Title VI of the 
Amsterdam Treaty). Thus, the overall objective of the Council Decision is to provide 
citizens with a high level of safety within an area of freedom, security and justice 
by developing common actions among the Member States in the fields of police 
and judicial cooperation in criminal matters. 
The Council Decision also clearly relates to the 1961 United Nations Single 
Convention on Narcotic Drugs (6) (hereafter the 1961 UN Convention) and the 
1971 United Nations Convention on Psychotropic Substances (7) (hereafter the 
1971 UN Convention). These conventions are relevant with regard to defining the 
scope of the Council Decision (Article 2) and the definition of new psychoactive 
substances (Article 3). Furthermore, they: affect the nature of the risk assessment 
(Article 6); can provide a basis for exclusion of a new psychoactive substance 
from risk assessment (Article 7) and; affect the measures of control to be taken by 
the Member States (Article 9). The relevance of the UN conventions for the risk 
assessment lies also in indicating the factors that should be taken into account 
when a risk assessment is carried out.
Further information on the procedures relating to the Early-warning system 
under the Council Decision can be found in the Early-warning system on new 
psychoactive substances — operating guidelines (8).
(5) OJ C 325, 24.12.2002.
(6) Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol 
amending the Single Convention on Narcotic Drugs, 1961, United Nations.
(7) Convention on Psychotropic Substances, 1971, United Nations.
(8) EMCDDA (2007), Early-warning system on new psychoactive substances — Operating 
guidelines, European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
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1.2 Scope
The scope of the Council Decision is defined in Article 2, which states that the 
Decision applies to substances not currently listed in any of the schedules to:
(a)  the 1961 UN Convention, that may pose a comparable threat to public health 
as the substances listed in Schedule I or II or IV thereof; and
(b)  the 1971 UN Convention, that may pose a comparable threat to public health 
as the substances listed in Schedule I or II or III or IV thereof.
The above implies that substances already listed under the UN conventions are 
excluded from the scope of the Council Decision. Important differences with 
the Joint Action are the inclusion of narcotic drugs as specified under (a) above 
and psychotropic substances posing a comparable threat as substances listed in 
Schedules III or IV of the 1971 UN Convention.
Although the new psychoactive substances concerned may include human or 
veterinary medicinal products (point 5 of the recital to the Council Decision), such 
products are excluded from a risk assessment under Article 7.3 of the Council 
Decision when the new psychoactive substance is used to manufacture a medicinal 
product which has been granted a marketing authorisation or for which an 
application has been made for a marketing authorisation or for which a marketing 
authorisation has been suspended by a competent authority.
Precursors used for the illicit manufacture of narcotic drugs and psychotropic 
substances are also excluded from the scope of the Council Decision. These are 
governed by different Regulations (9).
1.3 Factors to be considered in a risk assessment
According to Article 6.3 of the Council Decision, a risk assessment should take into 
account all factors which, according to the 1961 UN Convention or the 1971 UN 
Convention, would warrant placing a substance under international control. The 
(9) Council Regulation (EEC) No 3677/90 of 13 December 1990 laying down 
measures to be taken to discourage the diversion of certain substances to the illicit 
manufacture of narcotic drugs and psychotropic substance (OJ L 357, 20.12.1990); 
Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 
February 2004 on drug precursors (OJ L 47, 18.2.2004).
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factors that would warrant such action are described in Articles 3.3. (iii) and 3.5 
of the 1961 UN Convention and Article 2.4 of the 1971 UN Convention.
Based on the provisions in the UN conventions, the following need to be taken into 
account: 
1.  Whether a new psychoactive substance is liable to similar abuse (10) and 
produces similar ill effects as the drugs in Schedule I or Schedule II of the 1961 
UN Convention;
2.  Whether a new psychoactive substance is convertible into a drug as meant 
under point 1;
3.  Whether a new psychoactive substance is particularly liable to abuse and to 
produce ill effects and that such liability is not offset by substantial therapeutic 
advantages, which would qualify it for placement under Schedule IV of the 
1961 UN Convention;
4.  Whether the new psychoactive substance has the capacity to produce a state of 
dependence (11) and central nervous system stimulation or depression, resulting 
in hallucinations or disturbances in motor function or thinking or behaviour or 
perception or mood;
5.  Whether the new psychoactive substance is liable to similar abuse and similar 
ill effects as a substance listed in Schedules I, II, III or IV of the 1971 UN 
Convention;
(10) The terms ‘abuse’ and ‘use’ are used concomitantly throughout the guidelines. 
Whenever the text refers to the UN conventions or established terminology such as 
‘abuse potential’, the term ‘abuse’ is maintained. The EMCDDA preferred term ‘use’ 
appears when, for example, prevalence is discussed. 
(11) Dependence was defined by the WHO 28th Expert Committee on Drug Dependence 
as: ‘A cluster of physiological, behavioural and cognitive phenomena of variable 
intensity, in which the use of a psychoactive drug (or drugs) takes on a high priority. 
The necessary descriptive characteristics are preoccupation with a desire to obtain 
and take the drug and persistent drug-seeking behaviour. Determinants and the 
problematic consequences of drug dependence may be biological, psychological 
or social, and usually interact’ (WHO, 1993, WHO Expert Committee on Drug 
Dependence 28th Report, World Health Organization, Technical Report Series, 
Volume 386, Geneva.
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6.  If there is sufficient evidence that the substance is being or is likely to be abused 
so as to constitute a public health and social threat warranting placing the 
substance under international control.
According to Article 6.1 of the Council Decision, besides the above factors derived 
from the UN conventions, other aspects also need to be assessed. These are:
7.  The involvement of organised crime; and 
8.  The possible consequences of control measures.
Furthermore, according to Article 6.4 (g) of the Council Decision:
9.  Options for control and the possible consequences of control measures need to 
be reported.
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Chapter 2 
General considerations for risk assessment
When assessing the factors listed under section 1.3 in the previous chapter, the 
following general principles need to be taken into consideration.
2.1 A dual definition of risk
The concept of risk should be understood in its dual sense, which includes both the 
element of probability that some harm may occur (usually defined as ‘risk’) and 
the degree of seriousness of such a harm (usually defined as ‘hazard’). If possible, 
both elements should be evaluated in the final phase of the risk-assessment 
process.
2.2 Prevalence of use
Assessment if there is sufficient evidence that the substance is being or is likely to 
be used so as to constitute a public health and social threat is obligatory when 
the new psychoactive substance is a substance similar to those listed in the 1971 
UN Convention. However, it is also logical to consider this aspect for substances 
similar to those listed under the 1961 UN Convention. A substance for which it is 
anticipated that the extent of use will remain limited would not warrant measures 
of international control. 
When a new psychoactive substance is notified within the framework of the 
Council Decision, reporting will generally be based on anecdotal reports on the 
use of the new psychoactive substance or reports from laboratories or the police, 
or a combination thereof. At that stage, the spread of the substance will usually 
be low and prevalence of use likewise and triangulation of ethno-epidemiological 
methods will be needed to assess the extent of use among limited user groups. In 
most cases, an expert judgement will be needed on the likelihood that use of a 
new psychoactive substance will spread. This judgement will primarily be based 
on a comparison of the characteristics and accessibility of the new psychoactive 
substance and the setting in which the new psychoactive substance is used with 
the characteristics, accessibility and setting of use of other well-known substances. 
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Also, prevalence of use of the new psychoactive substance among specific groups 
could be indicative. Such groups may be drug users familiar with the use of similar 
psychoactive substances, e.g. stimulant users or users of opioids.
2.3 Potential benefits of the substance
In addition, and where feasible, the beneficial use of a new substance also needs 
to be considered to assess the risk-benefit ratio of each new substance. When new 
psychoactive substances have a therapeutic value, they will in some cases not be 
subjected to a risk assessment since such substances may, in line with Article 7.3 
of the Council Decision, be exempted from risk assessment. Furthermore, other 
factors such as economic value and industrial use may imply a benefit of the 
substance that also needs to be considered.
2.4 Risks of a substance, independently of its legal status
The scientific risk assessment of a particular substance should be carried out 
independently of its legal status in one or more of the European Union Member 
States.
2.5 Scientific evidence in relation to better-known substances
Since scientific evidence on new psychoactive substances will, by definition, 
often be limited, it will thus be necessary to evaluate the possible risks of these 
substances with reference to similar known substances. Such comparisons 
need not be restricted to illicit substances but may include licit substances with 
similar chemical characteristics, pharmacological actions or psychological and 
behavioural effects, or which offer relevant insights into the social risks presented 
by the substance. Similarly, when assessing the possible consequences of control 
measures, as presented in Chapter 4, it may be appropriate to examine relevant 
examples of control models involving licit or illicit substances. 
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2.6 Quality of data
In the final evaluation, the reliability of information (quality) needs to be weighed. 
As implied by the very nature of the assignment at hand, it will often be impossible 
to base the risk assessment of a new psychoactive substance on the evaluation 
of sound (reliable and valid) scientific knowledge. Pharmacological and socio-
scientific knowledge will accumulate over time and will therefore be compiled as 
social experience with the drug phenomenon in question develops. In the interim, 
risk assessments will have to be based on a broad range of available evidence. 
The quality of this evidence should be appraised according to the two following 
criteria:
2.6.1 Methodological characteristics of the available evidence
From a methodological point of view, evidence for risk assessment may be 
produced by more or less rigorous scientific procedures. Detailed biomedical 
data, based on systematic pharmacological and toxicological studies, will rarely 
be available for new psychoactive substances. In the case of socio-scientific data, 
evidence from preliminary, impressionistic accounts may be more available than 
evidence from more methodologically rigorous and objective studies, such as 
surveys or panel studies.
2.6.2 Sources of available evidence
The risk-assessment procedure should include a strategy for using data from 
sources of different quality. Evidence is likely to originate from sources with a 
wide range of reliability from peer-reviewed publications in prominent scientific 
journals, through, for example, reports by youth workers or psycho-medical 
institutions, to unsubstantiated media or Internet reports. A possible method of 
classifying this information is to use the type of ranking listed in the box below.
Adopting a differential strategy when accepting information may be the most 
sensible approach. In the first instance, the identification and collection of 
available data will involve accepting a wide range of information — including 
information that may be useful for signalling phenomena of possible relevance — 
and then applying different weights based on a hierarchy of data quality when 
screening the evidence to be considered in the final evaluation process.
24
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Classification of information sources
As data on new psychoactive substances is usually limited, the Scientific Committee 
should consider if the conclusions reached are justifiable, based on an assessment 
using incomplete data.
2.7 Weighing the issues of reliability and relevance separately
In the final evaluation, the issues of reliability of information (quality) as well as 
the relevance of the specific issues involved (health and social risks, involvement 
of organised crime and consequences of control measures) should be weighed 
separately. For example, unpublished recent data may be considered to have a 
lower formal quality, but still may be considered very relevant as often very recent 
data have not yet reached the status of a scientific publication in a peer-reviewed 
journal, or data might never be published. 
Peer-reviewed scientific publications •	
Official reports of international organisations and governmental institutions•	
Other reports and/or scientific publications•	
Unpublished data from forensic and clinical laboratories•	
 Other sources (EU databases, media, individual reports, unofficial publications •	
and the Internet)
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Chapter 3 
A conceptual framework for risk assessment
Risks related to any psychoactive substance — whether licit or illicit, medical or 
recreational — can originate from several sources and assume many shapes 
and forms. For both analytical and pragmatic purposes, it is essential to clarify 
both the type and origin of substance-related risks as they manifest themselves in 
society.
The following presents a conceptual framework within which elements of 
substance-related risk may be located and evaluated. The framework is built on 
the distinction between the sources from which substance hazards emanate (see 
box on p. 28) and the type of hazardous effects that may be caused by substance 
use (see box on p. 30).
3.1 Sources of hazards
Within the social reality of substance use, harmful effects may emanate from 
several domains which may exist independently of each other. Cannabis will 
serve as an example. Possible harmful consequences of use may be ‘caused’ by 
the substance’s pharmacological effects (properties of the substance), for instance 
when acute intoxication impedes the ability to drive a car and hence increases the 
chance of traffic accidents. Possible long-term effects on memory functions may be 
another case in point.
It is possible that careful and moderate use of cannabis may not coincide with any 
apparent undesirable psychological or somatic effect. However, harmful effects 
could emanate from moral stigmatisation or criminalisation of use of cannabis 
which, for instance, could result in the dismissal of cannabis users from school 
(measures of social control). In other cases, the undesirable effects might be 
contingent on the specific patterns and context of substance use.
28
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Sources of hazard
For clear examples, substances other than cannabis will need to be considered. 
Some of the well-known harmful effects of MDMA (ecstasy) are linked to the 
‘rave’ party context — prolonged and intensive dancing in badly ventilated, 
crowded areas which accentuate a pharmacological effect on body temperature. 
A well-known case of specific use patterns as a source of substance hazard is 
the relationship between intravenous substance use and HIV infection. The high 
prevalence of HIV infection in populations of drug users has less to do with the 
substances themselves and more to do with lifestyles (modalities of substance use).
There may also be interaction between the different sources of hazard 
themselves and this must also be taken into account. For example, whether or not 
pharmacological tolerance to opioids leads to injection is influenced by factors 
such as cultural setting, economic factors, formal policies and informal norms. 
Distinguishing domains from which the harmful effects of substances originate 
has obvious consequences for the drug policy options to be taken after the risk 
assessment procedure.
3.2 Hazardous effects
The harmful effects of substances and the drugs market can be conceived as 
having an impact on the user, the social environment of substance use and 
on society in general. In this case, it is inappropriate to assume that different 
hazardous effects are independent of each other.
Harmful effects on the user (biological, psychological, behavioural) tend to be 
directly linked to harmful effects on the social environment of substance use 
Sources of hazard emanating from:
intrinsic properties of the substance (pharmacology and toxicology)•	
measures of social control (regulatory policies and informal norms) •	
modalities of substance use (patterns, context of use)•	
individual characteristics of users (age, gender, genetics, personality)•	
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(family, neighbourhood and community, society at large) making dividing lines 
difficult to draw. Similarly, it is hard to make a clear distinction between the 
different ‘levels’ of harm caused to the user or to his or her social environment. 
Somatic effects will often have obvious consequences for psychological functions 
which, in turn, are also relevant for social behaviour. The example of alcohol 
illustrates this point: alcohol intoxication may cause cognitive dysfunction which, in 
turn, may lead to irresponsible social behaviour. 
Three aggregate levels can be distinguished in the social environment: the micro 
level (family); the meso level (neighbourhood and community); and the macro 
level (society at large). Particularly on the meso and macro levels, it is advisable 
to take note of the consequences of the substance distribution system separately. 
Independent of the properties of the substance, the nature of the illicit market may 
cause harmful effects, such as problems of public order and safety on the streets. 
On the macro level, the drug trade may be harmful for the integrity of economic 
or law-enforcement institutions. 
Despite the difficulties associated with interactions between different domains of 
harm and quantifying the level of harm, from a pragmatic view and to facilitate 
comparisons between different substances within certain domains, a semi-
quantitative approach is considered feasible on the basis of expert judgement. 
Thus, for analytical purposes and policy options, it is still useful to distinguish 
between different domains of harm. A semi-quantitative system of scoring is 
further addressed in Chapter 5 and Annex II and Annex III.
30
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Hazardous effects of a substance
(a) On the user:
biological (toxicity, dependence)•	
psychological (functional impairment, effects on personality)•	
behavioural (neglect of social roles, violence, etc.)•	
(b) On the social environment:
family — micro level (disruption, neglect, violence)•	
neighbourhood and community — meso level (public order and safety)•	
society at large — macro level (economy, public health and judicial systems)•	
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Chapter 4
Headings for the Risk Assessment Report
In any risk-assessment procedure, a number of headings are included under which 
the information is organised in a systematic manner. Article 6.4 of the Council 
Decision lists the headings as outlined below. To prepare the risk assessment and 
to facilitate the risk assessment process, the EMCDDA drafts a technical report 
using the format annexed to these guidelines (Annex I).
As outlined in Chapter 2, the probability (risk) and seriousness of the adverse 
consequences of a substance (hazard) should be taken into account at the 
beginning of the risk-assessment procedure. Under all headings, the specific 
substance should be studied in terms of its similarities to, and differences from, 
other relevant psychoactive substances, especially those for which established 
scientific literature exists. As also stated in Chapter 2, other relevant substances 
should be selected on the basis of their chemical and/or pharmacological 
resemblance to the substance concerned, or with regard to the insights they offer 
concerning social risks and the involvement of organised crime. This selection 
should not necessarily be restricted to illicit substances.
In assessing the risks of a particular psychoactive substance, six key variables 
likely to affect the hazards and risks related to that substance should be taken into 
consideration as outlined in the following box.
34
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Key variables
The information gathered during any risk-assessment process is likely to be based 
on different types of evidence as outlined in the following box.
Types of evidence
In evaluating the consistency between laboratory-based and population-based 
evidence, special account must be taken of social context factors, and of the 
selection of population groups and individual users as potential sources of bias 
when inferring the social and health risks of a specific substance.
(a) Physical, chemical and pharmacological description
The description of the new psychoactive substance should include its mechanism of 
action and its medical value. The description should include the elements set out in 
the following box.
Dose and frequency of use•	
Short-term and especially long-term effects•	
Interactions with other substances (including alcohol and medicines)•	
 Individual characteristics (e.g. genetic susceptibility, presence of interacting risk •	
factors)
Characteristics of the social and cultural environment•	
Involvement of organised crime•	
Laboratory evidence, either •	 in vitro or in vivo (mainly animals)
Evidence of effects on humans (biological and psychological)•	
Epidemiological evidence•	
Sociological evidence•	
Criminological evidence•	
35
Descriptive elements
(b) Health risks 
Possible health risks associated with the new psychoactive substance include 
both the risks to individual health, resulting from use, and the public health risks, 
affecting the broader community. There is not always a clear dividing line between 
individual and public health risks, nor between public health risks and social risks. 
Most health risks, especially individual ones, are likely to be the consequence of 
using the substance. However, some of the public health consequences may also 
be linked to the nature of the production and trafficking of the substance (e.g. 
the purity and quality of the substance on the market). Obviously, the extent of 
(anticipated) use (‘prevalence’) will mainly determine the level of concern for public 
health.
Individual health risks
Assessment of the individual health risks of a new psychoactive substance 
should cover physical and psychological, short-term and long-term aspects and 
should include the elements listed in the box below. Dose, frequency, route of 
administration and interactions with other substances are important factors to 
consider.
 Name of the substance, physical description and chemical composition. With •	
cross-reference to section (h) below, known or expected side-products or 
impurities should be mentioned
Known uses, and similarity to other relevant substances •	
 Pharmacological effects in animal and human studies, including its •	
pharmacodynamic actions on the central nervous system and on other organs 
and systems, its pharmacokinetics, and its psychological and behavioural effects 
on humans (cognition, mood, personality, behaviour, motor function)
36
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Elements for assessing individual health risks
Public health risks
Assessment of the public health risks of a new psychoactive substance should 
include epidemiological and other evidence as listed in the following box.
Elements for assessing public health risks
Acute toxicity, including safety profile and information on poisonings•	
 Chronic toxicity, including functional brain damage, reproductive toxicity, •	
genotoxicity and carcinogenic potential
Dependence potential (physical and psychological)•	
Psycho-social dysfunction•	
Similarities and differences to other reference substances •	
Extent, frequency and patterns of use•	
 Availability and quality of the new psychoactive substance on the market (purity, •	
adulterants, etc.)
 Availability of information, degree of knowledge and perceptions amongst users •	
concerning the psychoactive substance and its effects
Characteristics and behaviour of users (including risk factors, vulnerability, etc.)•	
 Nature and extent of health consequences (e.g. acute emergencies, poisonings, •	
road traffic accidents)
 Long-term consequences of use (e.g. irreversible toxicity leading to deterioration •	
of health at later stages of life)
 Conditions under which the new psychoactive substance is obtained and used, •	
including context-related effects and risks (e.g. continuous dancing in hot 
environments, other substances used)
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(c) Social risks
Some public health risks (e.g. road traffic accidents) could also be listed under the 
heading of social risks. Apart from such examples, social risks associated with the 
new psychoactive substance include the elements summarised in the following box.
Elements for assessing social risks
(d) Involvement of organised crime
Information on the level of involvement of organised crime and information on 
seizures and/or detections by the authorities, and the manufacture of the new 
psychoactive substance should be provided. 
There is no established definition of organised crime (12). However, for the purpose 
of these guidelines a broad definition by the UN (13) may be used: ‘Organised 
crime is understood to be the large-scale and complex criminal activity carried 
out by groups of persons, however loosely or tightly organised, for the enrichment 
of those participating and at the expense of the community and its members. 
(12) Definitions of Organised Crime (collected by Klaus von Lampe): http://www.
organized-crime.de/OCDEF1.htm
(13) United Nations, Changes in Forms and Dimensions of Criminality — Transnational 
and National, Working paper prepared by the Secretariat for the Fifth United 
Nations Congress on the Prevention of Crime and the Treatment of Offenders 
(Toronto, Canada, 1–12 September 1975).
 Individual social risks (e.g. impact on education or career, problems with •	
personal relationships)
Possible effects on direct social environment (e.g. neglect of family, violence)•	
Possible effects on society as a whole (public order and safety, acquisitive crime) •	
Economic costs (demands on health care)•	
Possible effects related to cultural context, for example marginalisation•	
 Possible appeal of the new psychoactive substance to specific population groups •	
within the general population
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It is frequently accomplished through ruthless disregard of any law, including 
offences against the person, and frequently in connection with political corruption’. 
A second useful and more contemporary definition is the one proposed by the 
European Commission (14) that incorporates part of the definition contained in 
Joint Action 98/733/JHA (15) and takes into consideration the advances reflected 
in the 2000 United Nations Convention against Transnational Organised Crime. 
It defines a criminal organisation as ‘a structured association, established over 
a period of time, of more than two persons, acting in concert with a view to 
committing offences which are punishable by deprivation of liberty or a detention 
order of a maximum of at least four years or a more serious penalty, as a means 
of obtaining, directly or indirectly, financial or other material benefits.’
Thus, important characteristics of organised crime that can be recognised are:
it is an activity of groups of people primarily aimed at financial gain;•	
criminal offences are committed by these groups in a systematic way with •	
serious consequences for society; and
these groups are prepared to protect themselves from law enforcement, •	
especially by means of the use of intimidation or violence, or by corruption.
Based on these characteristics, a number of elements are considered relevant for 
the involvement of organised crime in the production, trafficking and distribution of 
new psychoactive substances. These are summarised in the box below.
Elements for assessing the involvement of organised crime
(14) Brussels, 19 January 2005, COM/2005/0006 final — CNS/2005/0003.
(15) Joint Action adopted by the Council on the basis of Article K.3 of the Treaty on 
European Union, on making it a criminal offence to participate in a criminal 
organisation in the Member States of the European Union (OJ L 351 of 29.12.1998, 
p. 1).
 Evidence that criminal groups are systematically involved in production, •	
trafficking and distribution for financial gain
 Impact on the production, trafficking and distribution of other substances, •	
including existing as well as new psychoactive substances
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(e) Assessment of the new psychoactive substance in the United 
Nations system
In line with Article 2 of the Council Decision, substances that are listed in any of 
the schedules to the 1961 United Nations Single Convention on Narcotic Drugs 
(Schedules I, II or IV) or the 1971 United Nations Convention on Psychotropic 
Substances (Schedules I, II, III or IV) are excluded from a risk assessment. Similarly, 
as stated in Articles 7.1 and 7.2 of the Council Decision, the substance concerned 
may be at an advanced stage of assessment within the United Nations system 
or the new psychoactive substance has been assessed within the United Nations 
system, but a decision has been taken not to schedule it under the 1961 UN 
Convention or the 1971 UN Convention. In such cases, a risk assessment shall 
be carried out only if there is significant new information that is relevant in the 
framework of this Council Decision. It is therefore important to be informed about 
possible assessment procedures for the new psychoactive substance concerned 
within the United Nations system.
(f) Current control measures within the Member States
Where appropriate, a description of the control measures that are currently 
applicable to the new psychoactive substance in the Member States shall be 
 Evidence that the same groups or people are involved in different kinds of crime•	
 Impact of violence from criminal groups on society as a whole or on social •	
groups or local communities (public order and safety)
 Evidence of money-laundering practices, or impact of organised crime on other •	
socio-economical factors in society
 Economic costs and consequences (evasion of taxes or duties, costs to the judicial •	
system)
 Use of violence between or within criminal groups•	
 Evidence of strategies to prevent prosecution, for example through corruption or •	
intimidation
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provided. Thus, a description of various types of measures could be included 
(see box below). 
Examples of types of measures
(g) Options for control and possible consequences of the control measures
Under Article 9.1 of the Decision, the available control options are for the Member 
States to submit a new psychotropic substance to control measures and criminal 
penalties, as provided under their legislation, by virtue of their obligations under 
the 1971 United Nations Convention on Psychotropic Substances or the 1961 
United Nations Single Convention on Narcotic Drugs. However, Article 6.4 (g) 
requires the Risk Assessment Report to include the options for control and the 
possible consequences of the control measures. 
In assessing the possible consequences of control measures, it is appropriate to 
examine a range of control models (e.g. administrative or public health regulatory 
frameworks for alcohol, tobacco, medicines or poisons). The assessment should 
examine the consequences of different control options on the factors listed in the 
following box.
Prevention/education•	
Legally bound labelling•	
Establishing an age limit for users•	
Active monitoring •	
Intervention in production chain (precursors)•	
Legislation on medicines, poisons, food or consumer products•	
Control measures in accordance with 1961 and 1971 UN conventions•	
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Elements for examining the consequences of control options
(h) Chemical precursors used within the manufacturing process
Information on the chemical precursors that are used for the manufacture of the 
substance should be provided. Such information may come from analyses of 
chemicals found at production sites or from the literature. The description should 
include the elements set out in the box below.
Elements for description of chemical precursors
Production, trafficking and organised crime•	
Distribution and availability•	
Quality and price of the substance on the market•	
 Impact on the market and on the use of other substances (including the •	
likelihood of alternative new substances emerging)
Prevalence and patterns of use of the substance•	
Health consequences•	
Social consequences•	
 Other uses of the substance in pharmaceutical research, medicine, industry, •	
trade, etc.
Existing legislation, law enforcement, judicial and other control systems•	
 Specific cost implications (e.g. additional costs of product testing or forensic •	
analysis)
Chemicals found at production sites •	
Likely routes of synthesis•	
Impurities/side products of synthesis, if known•	
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Chapter 5 
Assessing the risks relative to other substances
In a final appraisal of the health and social risks in relation to the use of, 
manufacture of, and traffic in the new psychoactive substance, and the involvement 
of organised crime and the possible consequences of control measures, it is often 
very informative to make comparisons with other licit or illicit substances. For this, 
a method for quantifying these risks can be very helpful. However, few attempts 
have been made to introduce a quantitative method (van Amsterdam et al., 2004; 
Nutt et al., 2007). 
The use of a quantitative method is not obligatory, as the Council Decision does 
not describe in detail how such risks should be assessed. A methodology to aid 
the risk assessment derived from experience in the Netherlands and the UK has 
been annexed to these guidelines as a useful tool (see Annex II). Further progress 
in this field should be monitored for state-of-the-art knowledge.
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Chapter 6
Conclusion
The Risk Assessment Report should conclude by summarising the main issues 
addressed under the headings for the Risk Assessment Report as stipulated in  
Article 6.4, points (a) to (h) (see Chapter 4). It shall present a summary analysis  
of the scientific and law enforcement information available, and shall reflect  
all opinions held by the members of the Committee.
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Annex I
Technical report
The EMCDDA is responsible for the collection and assembly of data for a technical 
report, which should be prepared before the risk assessment takes place to 
facilitate the task. 
The technical report should be as thorough as possible, and balanced in its 
presentation. It should include the adequate and relevant data, including 
information already present in the Joint Report from the EMCDDA and Europol 
regarding the new psychoactive substance at hand, and any additional relevant 
information obtained from the Member States, the EMCDDA, Europol, the EMEA, 
WHO and the scientific literature. In order to accomplish this, the EMCDDA may 
seek assistance from advisers and ad hoc working groups.
The technical report should include, if available, information under the following 
headings:
A. Physical, chemical, pharmaceutical and pharmacological information
B. Dependence and abuse potential
C. Prevalence of use
D. Health risks
E. Social risks
F. Involvement of organised crime
Information on assessments within the United Nations system and on current 
control measures in Member States is already presented in the Europol–EMCDDA 
Joint Report on a new psychoactive substance and should only be updated by the 
EMCDDA if appropriate. 
The report should contain a summary of approximately 800 words.
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Section A  Physical, chemical, pharmaceutical and 
pharmacological information
The first section of the technical report describes basic information on the new 
psychoactive substance, its use, and its similarity to other substances.
A1. Physical, chemical, and pharmaceutical information
A1.1.  Physical and chemical description (including methods of synthesis, 
precursors, impurities if known — type and level)
A1.2.  Physical/pharmaceutical form (i.e. powder, capsules, tablets, liquids, 
injectables, cigarettes. Any distinctive markings, logos, etc., to be noted)
A1.3.  Route of administration and dosage (e.g. oral, inhalation, intravenous, 
etc.)
A2. Pharmacology, including pharmacodynamics and pharmacokinetics
A3. Psychological and behavioural effects
A4. Legitimate uses of the product
Section B Dependence and abuse potential
B1. Animal in vivo and in vitro data
B2. Human data
Section C Prevalence of use
For new psychoactive substances, there will usually be a lack of epidemiological 
prevalence data. Any information based on reports of use or seizures of the new 
psychoactive substance that can contribute to an estimate of the extent of use and 
any trends in extent, frequency and patterns of use should be included. 
Section D Health risks
When describing the health effects, similarities and dissimilarities with other better 
known psychoactive substances, both licit and illicit, should be made.
D1. Acute health effects
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D1.1.  Animal data 
Here, data regarding acute toxicity studies in animals, as well as safety 
pharmacology data can be mentioned, if available.
D1.2.  Human data 
Relevant acute adverse effects, both physical and psychological, reported 
by users, admissions to emergency rooms and reports on overdoses 
or fatal intoxications can be included. However, side effects noted in 
laboratory studies can also be included, if available. 
D2.  Chronic health effects
D2.1.  Animal data 
Chronic studies in animals are usually not available for new psychoactive 
substances. However, if available, any data on repeated dose toxicity, 
genotoxicity, carcinogenicity, reproductive toxicity or other forms of 
toxicity, including neurotoxicity can be mentioned in this section.
D2.2.  Human data 
For new psychoactive substances, long-term data on health effects in 
humans will usually be limited, if available at all. A description based 
on reports from users may be included, but also epidemiological data, 
if there is any. For chronic effects, the causal link with the use of the new 
psychoactive substance will in most cases be very difficult to establish, 
since numerous confounding factors will also be present. Both aspects of 
physical and psychological well-being should be considered.
D3. Factors affecting public health risks
  One factor of utmost importance affecting any potential health impact 
at population level is the prevalence of use. This aspect is described in 
Section C. Other factors influencing the impact on public health are:
D3.1.  Availability and quality of the new psychoactive substance on the market 
(purity, adulterants, etc.).
D3.2.  Availability of information, degree of knowledge and perceptions 
amongst users concerning the psychoactive substance and its effects.
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D3.3.  Characteristics and behaviours of users (including risk factors, 
vulnerability, etc.).
D3.4.  Nature and extent of health consequences (e.g. acute emergencies, road 
traffic accidents).
  Relevant information may already feature under section D.1. However, 
factors affecting the potential consequences for others are considered to 
be a public health issue (e.g. the likelihood of irresponsible behaviour, 
the extent of disturbance of executive function, decision making and the 
ability to control one’s movements).
D3.5.  Long-term consequences of use (e.g. irreversible toxicity leading to 
deterioration of health later in life).
D3.6.  Conditions under which the new psychoactive substance is obtained and 
used, including context-related effects and risks (e.g. continuous dancing 
in hot environments, other substances used).
Section E Social risks
E1.  Individual social risks 
Any effects known to impact on the social functioning of the individual 
user, e.g. impact on education or career and effects on personal 
relationships.
E2.  Possible effects on direct social environment  
Here, the consequences for the user’s social environment should be 
mentioned, such as neglect of family or violent behaviour.
E3.  Possible effects on society as a whole  
Effects such as disturbance of public order and safety and acquisitive 
crime should be described here.
E4.  Economic costs  
The economic impact of the use of the new psychoactive substance 
not related to the involvement of organised crime (which is mentioned 
under F), such as demands on health care, may be mentioned here.
E5.  Possible effects related to the cultural context, for example marginalisation
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E6.  Possible appeal of the new psychoactive substance to specific population 
groups within the general population.
Section F Involvement of organised crime
F1.  Evidence that criminal groups are systematically involved in production, 
trafficking and distribution for financial gain 
 Information on seizures and/or detections by the authorities, illegal 
laboratories or other production sites and distribution networks may be 
included here.
F2.  Impact on the production, trafficking and distribution of other substances, 
including existing psychoactive substances as well as new psychoactive 
substances 
 Information on the new psychoactive substance being produced at 
the same sites where other psychoactive substances are produced, the 
mixture of the new psychoactive substance with other psychoactive 
substances in the same product, and the use of the same distribution 
networks as those used for other psychoactive substances should be 
mentioned. 
F3.  Evidence of the same groups or people being involved in different kinds 
of crime 
 Mixing of different kinds of criminal activities by criminal groups is 
considered a characteristic of organised crime. Therefore, information on 
other kinds of crime committed by those involved should be mentioned 
here.
F4.  Impact of violence from criminal groups on society as a whole or on 
social groups or local communities (public order and safety) 
Evidence of adverse consequences of the use of violence by criminal 
groups involved on society or parts of it should be mentioned here. 
Also, possible consequences of unsafe production sites may be included 
here. Although not considered as ‘violence’ per se, it is indicative of the 
criminal group’s disregard for public safety.
F5.  Evidence of money-laundering practices, or impact of organised crime on 
other socio-economical factors in society 
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 Any adverse effects on the structure and function of financial and other 
markets, especially money laundering, should be mentioned here.
F6.  Economic costs and consequences (evasion of taxes or duties, costs to the 
judicial system)
F7. Use of violence between or within criminal groups
F8.  Evidence of strategies to prevent prosecution, for example through 
corruption or intimidation
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Annex II
Semi-quantitative assessment procedure
There are five major domains affecting the extent of risk: B (Dependence and 
abuse potential); C (Prevalence of use); D (Health risks); E (Social risks), and F 
(Involvement of organised crime). These five domains are further specified in 
Annex I: Technical report. Section A in the technical report is merely descriptive 
and does not determine the extent of risks associated with the new psychoactive 
substance.
Four of the five domains are divided into subgroups (B.1, B.2, etc.). Each subgroup 
receives a score based on expert judgement, taking into account the principles set 
out in the guidelines. The score obtained for each subgroup is called ‘risk level’ 
(RL). Domain C (Prevalence) receives only a single score.
As indicated in Chapter 2.1 of the guidelines, risk is to be understood and 
considered in its dual sense: both the degree of seriousness of harm (hazard) and 
the probability of harm. The expert is expected to make a judgement of the risk 
level comprised of an integrated assessment of both hazard and probability. In 
this respect, probability should be judged independently of prevalence of use, 
which is assessed separately under C. Thus, probability means the likelihood that 
a single user will be harmed.
Note that assigning scores for the sub-categories of the subgroups (i.e. D1.1 and 
D1.2) is not a requirement, as a panel of scientists is apt to give an integral (semi-)
quantitative judgement on each subgroup, provided their judgement is embedded 
in a Delphi-like environment. 
The Scientific Committee of the EMCDDA (if necessary, extended by a further five 
experts at most, and with up to two experts from the Commission, Europol and the 
EMEA (Article 6.2)) has the task to produce a report which gives a science-based 
(semi-)quantitative judgement on all aspects mentioned in the domains B to F. 
Based on this report, the Scientific Committee gives a final overall judgement of the 
risks of the new psychoactive substance and formulates a conclusion.
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Summary
The EMCDDA issues a technical report on the new psychoactive substance •	
containing information as specified in Annex I. The technical report also 
contains a summary of up to 800 words. This report forms the basis for the 
assessment of the new psychoactive substance.
The Scientific Committee of the EMCDDA produces a draft assessment report •	
which contains:
 — the technical report 
 —  the (semi-)quantitative judgment of the risks of the new psychoactive 
substance (or of the risk/benefit, if applicable). 
The draft assessment report is produced according to the procedure described •	
in this publication.
Based on this draft report, the Scientific Committee produces the final Risk •	
Assessment Report and formulates a conclusion.
Procedure
Step 1
The EMCDDA’s Scientific Committee consists of scientists with a variety of 
expertise, coming from different disciplinary backgrounds. If required, the Director 
of the EMCDDA, acting on the advice of the Chair of the Scientific Committee, 
can nominate up to five additional experts. Disciplines that may be necessary to 
complete a judgement of the new drug are: toxicology, pharmacology, neurology, 
psychology, psychiatry, sociology, economy, epidemiology, criminology, public 
health, trafficking (socio-psychology), judicial matters, medicines, teratology, and 
pulmonology (not limiting).
Step 2
All members receive the technical report and a sheet where they fill in their 
scores (see Annex III). For each of the 19 subgroups listed in domains B, D, E 
and F a judgement must be given, based on the technical report. Domain B 
has 2 subgroups; domain D: 3 subgroups; domain E: 6 subgroups; domain F: 
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8 subgroups. All members give numerical scores — on a scale from 0 to 4 — on 
the first written judgement sheet. 
 0 = No risk 
 1 = Minimal risk
 2 = Slight/small risk 
 3 = Moderate risk 
 4 = Severe risk 
In addition to their numerical scores, experts may write short remarks or comments 
on the sheet to motivate their score or to draw attention to specific aspects.
Remarks to numerical scores:
Experts only score subgroups where they have expertise. In a separate box on •	
the first judgement sheet the expert can also indicate that the subgroup was 
not scored (reason for not scoring may be no expertise or no data available).
Definition: the 19 numerical scores are the 19 ‘risk levels’ (RL).•	
Definition: the five (mean) values of the five domains are the five ‘average risk’ •	
values (AR).
In addition, a score must be assigned to the prevalence factor (domain C), which is a 
modifying parameter affecting the extent (impact) of (public) health risks and social 
risks.
Although precise figures for prevalence of use will not usually be available, the 
expert is expected to make a judgement based on available ethno-epidemiological 
data. Moreover, as the risk assessment takes place within the framework of the 
Council Decision, which is aimed at assessment at an early phase, prevalence of 
use will in most cases still be very limited. Instead of looking at prevalence among 
the general population, prevalence among specific groups could be indicative. 
Such groups can be groups of drug users, familiar with the use of similar 
psychoactive substances, e.g. stimulant users or users of opioids. 
Furthermore, the Scientific Committee is expected to consider evidence that the 
substance is being or is likely to be used in a manner that constitutes a public 
health and/or social threat. An expert judgement can therefore be given on 
60
Risk assessment of new psychoactive substances: operating guidelines
the anticipated level of use, based on a comparison of the characteristics and 
accessibility of the new psychoactive substance and the settings in which it is 
used with the characteristics, accessibility and settings of use of other well-known 
substances.
Based on these two approaches, the following matrix can be used to score 
‘prevalence’:
Prevalence 
score
Prevalence of use in specific drug 
user groups
Anticipated level of use 
in general population
0 Only a few individuals have been 
reported
Only a few individuals
1 (low) More than anecdotal reports, but last 
year prevalence (LYP) < 5 %
LYP < 0.2 % 
2 (moderate) LYP ≥ 5 % LYP ≥ 0.2 %
3 (high) LYP ≥ 20 % LYP ≥ 1 % 
Step 3
The experts send their sheets with the scores (and remarks) by e-mail to the Chair 
of the Scientific Committee who makes an overall summary of the judgement 
sheets. This will contain:
 i) a copy of all judgement sheets
 ii)  the mean value of the individual RLs given for the 19 subgroups, arranged 
per subgroup 
  iii) the average risk (AR) value of the five domains 
  iv)  the list with subgroups on which there is agreement/consensus (similar 
score by all experts; variation in score ≤ 1)
  v)  the list with subgroups on which there is apparent disagreement (a range 
of different RLs given for a subgroup in which the variation > 1)
  vi) the list of all remarks arranged per subgroup.
The overall summary is distributed to all members by e-mail.
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Step 4
Delphi approach:  
On the day of decision, the Chair discusses with all members of the Scientific 
Committee points v and vi of the overall summary.
Step 5
Following a Delphi approach/discussion, each expert is allowed to change his/her 
numerical score on the second judgement sheet. 
Step 6
The Chair produces the draft assessment report that includes:
a copy of all second judgement sheets•	
the mean value of the (revised) individual RLs for the 19 subgroups, arranged •	
per subgroup
the average risk (AR) value of the five domains.•	
Step 7
The EMCDDA’s Scientific Committee makes a final judgement on the risks of the 
new psychoactive substance taking into account the draft assessment report, 
formulates a conclusion and produces the final Risk Assessment Report.
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Meaning of the Risk Level (RL) values
0 = No risk
1 = Minimal risk
2 = Slight/small risk
3 = Moderate risk
4 = Severe risk
n = No expertise/no data/not relevant
Name of the expert:
Date:
Substance under evaluation:
Annex III
Expert’s scoring form
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Summary of the technical report
Summary of a maximum of 800 words, to be provided by the EMCDDA.
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Domain B: Dependence and abuse potential
B1. Animal in vivo and in vitro data
 RL:  0  1  2  3  4      n 
B2. Human data
 RL:  0  1  2  3  4      n 
Expert’s comments:
Expert’s comments:
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Domain C: Prevalence of use
Prevalence 
score
Prevalence of use in specific drug 
user groups
Anticipated level of use 
in general population
0 Only a few individuals have been 
reported
Only a few individuals
1 (low) More than anecdotal reports, but last 
year prevalence (LYP) < 5 %
LYP < 0.2 % 
2 (moderate) LYP ≥ 5 % LYP ≥ 0.2 %
3 (high) LYP ≥ 20 % LYP ≥ 1 % 
 RL:  0  1  2  3       n 
Expert’s comments:
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Domain D: Health risks
D1. Acute health effects
 RL:  0  1  2  3  4      n 
D2. Chronic health effects
 RL:  0  1  2  3  4      n 
D3. Factors affecting public health risks
 RL:  0  1  2  3  4      n 
Expert’s comments:
Expert’s comments:
Expert’s comments:
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Domain E: Social risks
E1. Individual social risks
 RL:  0  1  2  3  4      n 
E2. Possible effects on direct social environment
 RL:  0  1  2  3  4      n 
E3. Possible effects on society as a whole
 RL:  0  1  2  3  4      n 
Expert’s comments:
Expert’s comments:
Expert’s comments:
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E4. Economic costs
 RL:  0  1  2  3  4      n 
E5. Possible effects related to the cultural context, for example marginalisation
 RL:  0  1  2  3  4      n 
E6. Possible appeal of the new psychoactive substance to specific population 
groups within the general population
 RL:  0  1  2  3  4      n 
Expert’s comments:
Expert’s comments:
Expert’s comments:
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Domain F: Involvement of organised crime
F1. Evidence that criminal groups are systematically involved in production, 
trafficking and distribution for financial gain
 RL:  0  1  2  3  4      n 
F2. Impact on the production, trafficking and distribution of other substances, 
including existing psychoactive substances as well as new psychoactive 
substances
 RL:  0  1  2  3  4      n 
F3. Evidence of the same groups or people being involved in different kinds of 
crime
 RL:  0  1  2  3  4      n 
Expert’s comments:
Expert’s comments:
Expert’s comments:
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F4. Impact of violence from criminal groups on society as a whole or on social 
groups or local communities (public order and safety)
 RL:  0  1  2  3  4      n 
F5. Evidence of money-laundering practices, or impact of organised crime on 
other socio-economical factors in society
 RL:  0  1  2  3  4      n 
F6. Economic costs and consequences (evasion of taxes or duties, costs to the 
judicial system)
 RL:  0  1  2  3  4      n 
Expert’s comments:
Expert’s comments:
Expert’s comments:
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F7. Use of violence between or within criminal groups
 RL:  0  1  2  3  4      n 
F8. Evidence of strategies to prevent prosecution, for example through corruption 
or intimidation
 RL:  0  1  2  3  4      n 
Expert’s comments:
Expert’s comments:
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Appendix
Council Decision 2005/387/JHA of 10 May 2005 
on the information exchange,  
risk-assessment and control of new  
psychoactive substances
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on European Union, and in particular Articles 29, 
31(1)(e) and 34(2)(c) thereof,
Having regard to the proposal from the Commission,
Having regard to the opinion of the European Parliament [16],
Whereas:
(1) The particular dangers inherent in the development of psychoactive 
substances require rapid action by the Member States.
(2) When new psychoactive substances are not brought within the scope of 
criminal law in all Member States, problems may arise in cooperation 
between the judicial authorities and law enforcement agencies of Member 
States owing to the fact that the offence or offences in question are not 
punishable under the laws of both the requesting and the requested State.
(3) The European Union Action Plan on Drugs 2000-2004 provided for the 
Commission to organise an appropriate assessment of the Joint Action of 
16 June 1997 concerning the information exchange, risk assessment and the 
control of new synthetic drugs [17] (herineafter ‘the Joint Action’) taking into 
account the external evaluation commissioned by the European Monitoring 
Centre on Drugs and Drug Addiction (hereinafter ‘the EMCDDA’) of the early 
(16) Opinion delivered on 13 January 2004 (not yet published in the Official Journal).
(17) OJ L 167, 25.6.1997, p. 1.
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warning system. The assessment showed that the Joint Action had fulfilled 
its expectations. Nevertheless, the outcome of the assessment made it clear 
that the Joint Action was in need of reinforcement and reorientation. In 
particular, its main objective, the clarity of its procedures and definitions, 
the transparency of its operation, and the relevance of its scope had to 
be redefined. The Communication from the Commission to the European 
Parliament and the Council on the mid-term evaluation of the EU Action 
Plan on Drugs (2000-2004) indicated that changes to the legislation would 
be introduced in order to enhance action against synthetic drugs. The 
mechanism as established by the Joint Action should therefore be adapted.
(4) New psychoactive substances can be harmful to health.
(5) The new psychoactive substances covered by this Decision may include 
medicinal products as defined in Directive 2001/82/EC of the European 
Parliament and of the Council of 6 November 2001 on the Community Code 
relating to veterinary medicinal products [18] and in Directive 2001/83/EC 
of the European Parliament and of the Council of 6 November 2001 on the 
Community Code relating to medicinal products for human use [19].
(6) The information exchange under the early warning system, established under 
the Joint Action, has proved to be a valuable asset to the Member States.
(7) Nothing in this Decision should prevent Member States from exchanging 
information, within the European Information Network on Drugs and Drug 
Addiction (hereinafter ‘the Reitox network’), on emerging trends in new uses 
of existing psychoactive substances which may pose a potential risk to public 
health, as well as information on possible public health related measures, in 
accordance with the mandate and procedures of the EMCDDA.
(8) No deterioration of either human or veterinary health care as a result of this 
Decision will be permitted. Substances of established and acknowledged 
medical value are therefore excluded from control measures based on this 
(18) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC 
(OJ L 136, 30.4.2004, p. 58).
(19) OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive 2004/27/EC 
(OJ L 136, 30.4.2004, p. 34).
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Decision. Suitable regulatory and public health related measures should be 
taken for substances of established and acknowledged medical value that are 
being misused.
(9) In addition to what is provided for under the pharmacovigilance systems as 
defined in Directive 2001/82/EC and in Directive 2001/83/EC, the exchange 
of information on abused or misused psychoactive substances needs to 
be reinforced and appropriate cooperation with the European Medicines 
Agency (hereinafter ‘EMEA’) ensured. The United Nations Commission on 
Narcotic Drugs (hereinafter ‘CND’) Resolution 46/7 ‘Measures to promote the 
exchange of information on new patterns of drug use and on psychoactive 
substances consumed’, provides a useful framework for action by the Member 
States.
(10) The introduction of deadlines into every phase of the procedure established 
by this Decision should guarantee that the instrument can react swiftly and 
enhances its ability to provide a quick-response mechanism.
(11) The Scientific Committee of the EMCDDA has a central role in the assessment 
of the risks associated with a new psychoactive substance, it will for the 
purpose of this Decision be extended to include experts from the Commission, 
Europol and the EMEA, and experts from scientific fields not represented, or 
not sufficiently represented, in the Scientific Committee of the EMCDDA.
(12) The extended Scientific Committee that assesses the risks associated with new 
psychoactive substances should remain a concise technical body of experts, 
capable of assessing effectively all risks associated with a new psychoactive 
substance. Therefore the extended Scientific Committee should be kept to a 
manageable size.
(13) Since the objectives of the proposed action, namely to bring about an 
exchange of information, a risk-assessment by a scientific committee and an 
EU-level procedure for bringing notified substances under control, cannot be 
sufficiently achieved by the Member States and can therefore, by reason of 
the effects of the envisaged action, be better achieved at European Union 
level, the Union may adopt measures, in accordance with the principle of 
subsidiarity as set out in Article 5 of the Treaty. In accordance with the 
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principle of proportionality as set out in that Article, this Decision does not go 
what is beyond what is necessary in order to achieve those objectives
(14) In conformity with Article 34(2)(c) of the Treaty, measures based upon this 
Decision can be taken by qualified majority as these measures are necessary 
to implement this Decision.
(15) This Decision respects fundamental rights and observes the principles 
recognised by Article 6 of the Treaty and reflected in the Charter of 
Fundamental Rights of the European Union,
HAS DECIDED AS FOLLOWS:
Article 1
Subject matter
This Decision establishes a mechanism for a rapid exchange of information on 
new psychoactive substances. It takes note of information on suspected adverse 
reactions to be reported under the pharmacovigilance system as established by 
Title IX of Directive 2001/83/EC.
This Decision also provides for an assessment of the risks associated with these 
new psychoactive substances in order to permit the measures applicable in the 
Member States for control of narcotic and psychotropic substances to be applied 
also to new psychoactive substances.
Article 2
Scope
This Decision applies to substances not currently listed in any of the schedules to:
(a) the 1961 United Nations Single Convention on Narcotic Drugs, that may pose 
a comparable threat to public health as the substances listed in Schedule I or 
II or IV thereof, and
(b) the 1971 United Nations Convention on Psychotropic Substances, that 
may pose a comparable threat to public health as the substances listed in 
Schedule I or II or III or IV thereof.
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This Decision relates to end-products, as distinct from precursors in respect of 
which Council Regulation (EEC) No 3677/90 of 13 December 1990 laying down 
measures to be taken to discourage the diversion of certain substances to the illicit 
manufacture of narcotic drugs and psychotropic substances [20], and Regulation 
(EC) No 273/2004 of the European Parliament and of the Council of 11 February 
2004 on drug precursors [21] provide for a Community regime.
Article 3
Definitions
For the purpose of this Decision the following definitions shall apply:
(a) ‘new psychoactive substance’ means a new narcotic drug or a new 
psychotropic drug in pure form or in a preparation;
(b) ‘new narcotic drug’ means a substance in pure form or in a preparation, that 
has not been scheduled under the 1961 United Nations Single Convention on 
Narcotic Drugs, and that may pose a threat to public health comparable to 
the substances listed in Schedule I, II or IV;
(c) ‘new psychotropic drug’ means a substance in pure form or in a preparation 
that has not been scheduled under the 1971 United Nations Convention 
on Psychotropic Substances, and that may pose a threat to public health 
comparable to the substances listed in Schedule I, II, III or IV;
(d) ‘marketing authorisation’ means a permission to place a medicinal product 
on the market, granted by the competent authority of a Member State, 
as required by Title III of Directive 2001/83/EC (in the case of medicinal 
products for human use) or Title III of Directive 2001/82/EC (in the case of 
veterinary medicinal products) or a marketing authorisation granted by the 
European Commission under Article 3 of Regulation (EC) No 726/2004 of 
the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal 
(20) OJ L 357, 20.12.1990, p. 1. Regulation as last amended by Commission Regulation 
(EC) No 1232/2002 (OJ L 180, 10.7.2002, p. 5).
(21) OJ L 47, 18.2.2004, p. 1.
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products for human and veterinary use and establishing a European 
Medicines Agency [22];
(e) ‘United Nations system’ means the World Health Organisation (WHO), 
the Commission on Narcotic Drugs (CND) and/or the Economic and Social 
Committee acting in accordance with their respective responsibilities as 
described in Article 3 of the 1961 United Nations Single Convention on 
Narcotic Drugs or in Article 2 of the 1971 United Nations Convention on 
Psychotropic Substances;
(f) ‘preparation’ means a mixture containing a new psychoactive substance;
(g) ‘Reporting Form’ means a structured form for notification of a new 
psychoactive substance and/or of a preparation containing a new 
psychoactive substance agreed between the EMCDDA/Europol and their 
respective networks in the Member States’ Reitox and the Europol National 
Units.
Article 4
Exchange of information
1. Each Member State shall ensure that its Europol National Unit and its 
representative in the Reitox network provide information on the manufacture, 
traffic and use, including supplementary information on possible medical 
use, of new psychoactive substances and of preparations containing new 
psychoactive substances, to Europol and the EMCDDA, taking into account 
the respective mandates of these two bodies.
 Europol and the EMCDDA shall collect the information received from 
Member States through a Reporting Form and communicate this information 
immediately to each other and to the Europol National Units and the 
representatives of the Reitox network of the Member States, the Commission, 
and to the EMEA.
2. Should Europol and the EMCDDA consider that the information provided 
by a Member State on a new psychoactive substance does not merit the 
(22) OJ L 136, 30.4.2004, p. 1.
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communication of information as described in paragraph 1, they shall inform 
the notifying Member State immediately thereof. Europol and the EMCDDA 
shall justify their decision to the Council within six weeks.
Article 5
Joint Report
1. Where Europol and the EMCDDA, or the Council, acting by a majority of its 
members, consider that the information provided by the Member State on a 
new psychoactive substance merits the collection of further information, this 
information shall be collated and presented by Europol and the EMCDDA 
in the form of a Joint Report (hereinafter the ‘Joint Report’). The Joint Report 
shall be submitted to the Council, the EMEA and the Commission.
2. The Joint Report shall contain:
(a) a chemical and physical description, including the name under which the new 
psychoactive substance is known, including, if available, the scientific name 
(International Non-proprietary Name);
(b) information on the frequency, circumstances and/or quantities in which a new 
psychoactive substance is encountered, and information on the means and 
methods of manufacture of the new psychoactive substance;
(c) information on the involvement of organised crime in the manufacture or 
trafficking of the new psychoactive substance;
(d) a first indication of the risks associated with the new psychoactive substance, 
including the health and social risks, and the characteristics of users;
(e) information on whether or not the new substance is currently under 
assessment, or has been under assessment, by the UN system;
(f) the date of notification on the Reporting Form of the new psychoactive 
substance to the EMCDDA or to Europol;
(g) information on whether or not the new psychoactive substance is already 
subject to control measures at national level in a Member State;
(h) as far as possible, information will be made available on:
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(i) the chemical precursors that are known to have been used for the 
manufacture of the substance,
(ii) the mode and scope of the established or expected use of the new substance,
(iii) any other use of the new psychoactive substance and the extent of such use, 
the risks associated with this use of the new psychoactive substance, including 
the health and social risks.
3. The EMEA shall submit to Europol and the EMCDDA the following 
information on whether in the European Union or in any Member State:
(a) the new psychoactive substance has obtained a marketing authorisation;
(b) the new psychoactive substance is the subject of an application for a 
marketing authorisation;
(c) a marketing authorisation that had been granted in respect of the new 
psychoactive substance has been suspended.
Where this information relates to marketing authorisations granted by Member 
States, these Member States shall provide the EMEA with this information if so 
requested by it.
4. Member States shall provide the details referred to under paragraph 2 within 
six weeks from the date of notification on the Reporting Form as set out in 
Article 4(1).
5. The Joint Report shall be submitted no more than four weeks after the 
date of receipt of the information from Member States and the EMEA. The 
Report shall be submitted by Europol or the EMCDDA, as appropriate, in 
accordance with Article 5(1) and (2).
Article 6
Risk assessment
1. The Council, taking into account the advice of Europol and the EMCDDA, and 
acting by a majority of its members, may request that the risks, including the 
health and social risks, caused by the use of, the manufacture of, and traffic 
in, a new psychoactive substance, the involvement of organised crime and 
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possible consequences of control measures, be assessed in accordance with 
the procedure set out in paragraphs 2 to 4, provided that at least a quarter 
of its members or the Commission have informed the Council in writing 
that they are in favour of such an assessment. The Member States or the 
Commission shall inform the Council thereof as soon as possible, but in any 
case within four weeks of receipt of the Joint Report. The General Secretariat 
of the Council shall notify this information to the EMCDDA without delay.
2. In order to carry out the assessment, the EMCDDA shall convene a special 
meeting under the auspices of its Scientific Committee. In addition, for the 
purpose of this meeting the Scientific Committee may be extended by a 
further five experts at most, to be designated by the Director of the EMCDDA, 
acting on the advice of the Chairperson of the Scientific Committee, chosen 
from a panel of experts proposed by Member States and approved every 
three years by the Management Board of the EMCDDA. Such experts will be 
from scientific fields that are not represented, or not sufficiently represented, 
in the Scientific Committee, but whose contribution is necessary for the 
balanced and adequate assessment of the possible risks, including health and 
social risks. Furthermore, the Commission, Europol and the EMEA shall each 
be invited to send a maximum of two experts.
3. The risk assessment shall be carried out on the basis of information to be 
provided to the scientific Committee by the Member States, the EMCDDA, 
Europol, the EMEA, taking into account all factors which, according to the 
1961 United Nations Single Convention on Narcotic Drugs or the 1971 
United Nations Convention on Psychotropic Substances, would warrant the 
placing of a substance under international control.
4. On completion of the risk assessment, a report (hereinafter the ‘Risk 
Assessment Report’) shall be drawn up by the Scientific Committee. The 
Risk Assessment Report shall consist of an analysis of the scientific and law 
enforcement information available, and shall reflect all opinions held by the 
members of the Committee. The Risk Assessment Report shall be submitted 
to the Commission and Council by the chairperson of the Committee, on 
its behalf, within a period of twelve weeks from the date of the notification 
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by the General Secretariat of the Council to the EMCDDA referred to in 
paragraph 1.
The Risk Assessment Report shall include:
(a) the physical and chemical description of the new psychoactive substance and 
its mechanisms of action, including its medical value;
(b) the health risks associated with the new psychoactive substance;
(c) the social risks associated with the new psychoactive substance;
(d) information on the level of involvement of organised crime and information 
on seizures and/or detections by the authorities, and the manufacture of the 
new psychoactive substance;
(e) information on any assessment of the new psychoactive substance in the 
United Nations system;
(f) where appropriate, a description of the control measures that are applicable 
to the new psychoactive substance in the Member States;
(g) options for control and the possible consequences of the control measures, 
and
(h) the chemical precursors that are used for the manufacture of the substance.
Article 7
Circumstances where no risk assessment is carried out
1. No risk assessment shall be carried out in the absence of a Europol/EMCDDA 
Joint Report. Nor shall a risk assessment be carried out where the new 
psychoactive substance concerned is at an advanced stage of assessment 
within the United Nations system, namely once the WHO expert committee 
on drug dependence has published its critical review together with a written 
recommendation, except where there is significant new information that is 
relevant in the framework of this Decision.
2. Where the new psychoactive substance has been assessed within the United 
Nations system, but it has been decided not to schedule the new psychoactive 
substance under the 1961 Single Convention on Narcotic Drugs or the 1971 
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Convention on Psychotropic Substances, a risk assessment shall be carried out 
only if there is significant new information that is relevant in the framework of 
this Decision.
3. No risk assessment shall be carried out on a new psychoactive substance if:
(a) the new psychoactive substance is used to manufacture a medicinal product 
which has been granted a marketing authorisation; or,
(b) the new psychoactive substance is used to manufacture a medicinal product 
for which an application has been made for a marketing authorisation or,
(c) the new psychoactive substance is used to manufacture a medicinal product 
for which a marketing authorisation has been suspended by a competent 
authority.
Where the new psychoactive substance falls into one of the categories listed 
under the first subparagraph, the Commission, on the basis of data collected by 
EMCDDA and Europol, shall assess with the EMEA the need for further action, in 
close cooperation with the EMCDDA and in accordance with the mandate and 
procedures of the EMEA.
The Commission shall report to the Council on the outcome.
Article 8
Procedure for bringing specific new psychoactive substances under control
1. Within six weeks from the date on which it received the Risk Assessment 
Report, the Commission shall present to the Council an initiative to have the 
new psychoactive substance subjected to control measures. If the Commission 
deems it is not necessary to present an initiative on submitting the new 
psychoactive substance to control measures, within six weeks from the date 
on which it received the Risk Assessment Report, the Commission shall present 
a report to the Council explaining its views.
2. Should the Commission deem it not necessary to present an initiative on 
submitting the new psychoactive substance to control measures, such an 
initiative may be presented to the Council by one or more Member States, 
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preferably not later than six weeks from the date on which the Commission 
presented its report to the Council.
3. The Council shall decide, by qualified majority and acting on an initiative 
presented pursuant to paragraph 1 or 2, on the basis of Article 34(2)(c) 
of the Treaty, whether to submit the new psychoactive substance to control 
measures.
Article 9
Control measures taken by Member States
1. If the Council decides to submit a new psychoactive substance to control 
measures, Member States shall endeavour to take, as soon as possible, but 
no later than one year from the date of that decision, the necessary measures 
in accordance with their national law to submit:
(a) the new psychotropic drug to control measures and criminal penalties as 
provided under their legislation by virtue of their obligations under the 1971 
United Nations Convention on Psychotropic Substances;
(b) the new narcotic drug to control measures and criminal penalties as provided 
under their legislation by virtue of their obligations under the 1961 United 
Nations Single Convention on Narcotic Drugs.
2. Member States shall report the measures taken to both the Council and the 
Commission as soon as possible after the relevant decision has been taken. 
Thereafter this information shall be communicated to the EMCDDA, Europol, 
the EMEA, and the European Parliament.
3. Nothing in this Decision shall prevent a Member State from maintaining or 
introducing on its territory any national control measure it deems appropriate 
once a new psychoactive substance has been identified by a Member State.
Article 10
Annual report
The EMCDDA and Europol shall report annually to the European Parliament, the 
Council and the Commission on the implementation of this Decision. The report 
will take into account all aspects required for an assessment of the efficacy and 
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achievements of the system created by this Decision. The Report shall, in particular, 
include experience relating to coordination between the system set out in this 
Decision and the pharmacovigilance system.
Article 11
Pharmacovigilance system
Member States and the EMEA shall ensure an appropriate exchange of 
information between the mechanism set up by means of this Decision and the 
pharmacovigilance systems as defined and established under Title VII of Directive 
2001/82/EC and Title IX of Directive 2001/83/EC.
Article 12
Repeal
The Joint Action on New Synthetic Drugs of 16 June 1997 is hereby repealed. 
Decisions taken by the Council based on Article 5 of that Joint Action shall 
continue to be legally valid.
Article 13
Publication and taking effect
This Decision shall take effect on the day following that of its publication in the 
Official Journal of the European Union.
Done at Brussels, 10 May 2005.
For the Council 
The President 
J. Krecké
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